Cadila Of India To Reveal Soon New Breakthrough Drug Candidate
This article was originally published in PharmAsia News
India's Cadila Pharmaceuticals says it plans to introduce soon a drug it expects to lower by one-third the cost of treating tuberculosis. Cadila said it expects to announce the drug Resorine (resorcin) within the next two weeks. Chairman I.A. Modi called the drug a bio-enhancer capable of lowering the dosage of existing TB drugs without sacrificing efficacy. The Cadila drug already has completed Phase III trials and has special protocol approval by U.S. FDA. The Cadila announcement comes just three months after it unveiled its Polycap (atenolol/thiazide) cardiac drug, which it considers a potential blockbuster. (Click here for more
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.